Diazoxide-Associated Pulmonary Hypertension in an Infant with Beck with-Wiedemann Syndrome: A Case Report

• Published in: Perinatology (Online) Vol. 33; no. 1; pp. 37 - 42
• Main Authors: Ryu, Jae Hui, Kang, Dayun, Lee, Joowon, Ko, Jung Min, Jung, Young Hwa, Kim, Jae Hyun, Choi, Chang Won
• Format: Journal Article
• Language: English
• Published: 대한주산의학회 01.03.2022
• Subjects: 의학일반
• ISSN: 2508-4887; 2508-4895
• DOI: 10.14734/PN.2022.33.1.37

Diazoxide, an ATP-sensitive potassium channel opener, has been used as 1st line treatment for hyperinsulinemic hypoglycemia. As congenital hyperinsulinism is the most common cause of hyperinsulinemic hypoglycemia, diazoxide is more often used in neonates and infants than in adults. In 2015, the United States Food and Drug Administration issued a safety alert cautioning about pulmonary hypertension (PH) in children treated with diazoxide. Fluid overload prior to diazoxide administration and the presence of congenital heart disease have been known as risk factors for PH developing after diazoxide administration in children. Herein, we report a case of an infant with congenital hyperinsulinism associated with Beckwith-Wiedemann syndrome which developed PH after diazoxide administration. This is the first report of diazoxide-associated PH in Korea, which emphasizes the need for special awareness on this life-threatening side effect of diazoxide treatment in children. KCI Citation Count: 0